SavedAdd your journal

Journals / Eurasian Journal of Medical Investigation / 2021 / Cilt: 5 - Sayı: 4

Does Platelet Count Affect Survival Outcomes in Patients with Malignant Pleural Mesothelioma?

Alper Sonkaya
Ozgur Acikgoz
Kazim Uygun
Pages
508–514
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: Overall survival (OS) of the entire population was 11.5 months (%95 CI; 5.86-17.19) In multivariate analysis we found a statistically significant correlation with platelet count and progression free survival (p=0.001).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Malign mesothelioma arises from pleura, peritoneum, pericardium and tunica vaginalis of testis.
📊
Key Findings & Data:It is seen relatively low but has a high mortality rate.
💡
Conclusion & Impact:Results: Overall survival (OS) of the entire population was 11.5 months (%95 CI; 5.86-17.19) In multivariate analysis we found a statistically significant correlation with platelet count and progression free survival (p=0.001).
🔬Design:Review & Systematic Survey
📍Scope:2008 Verileri
⚙️Variables:Domain Parameters

Abstract

Objectives: Malign mesothelioma arises from pleura, peritoneum, pericardium and tunica vaginalis of testis. It is a primary malignant tumor that originates from mesothelial cells. It is seen relatively low but has a high mortality rate. Methods: In this study, we reviewed 41 (Malignant Pleural Mesothelioma) MPM patients who were admitted to Kocaeli University Department of Oncology between 2008 and 2014 retrospectively. Patient data were reviewed from medical records. We retrospectively analyzed the correlation between the clinical characteristics, complete blood count param- eters and survival in patients with MPM. Results: Overall survival (OS) of the entire population was 11.5 months (%95 CI; 5.86-17.19) In multivariate analysis we found a statistically significant correlation with platelet count and progression free survival (p=0.001). In our study overall survival was better in left pleura localized primary tumors, early staged tumors and patients with platelet count lower than 400.000 μl. Conclusion: Early stage disease and low platelet count have a significant prognostic importance at the time of diagnos

🔖

Cite This Article

Sonkaya, A., Acikgoz, O., Uygun, K. (2022). Does Platelet Count Affect Survival Outcomes in Patients with Malignant Pleural Mesothelioma?. Eurasian Journal of Medical Investigation, Cilt: 5 - Sayı: 4, 508–514. https://ajindex.com/articles/508566

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet 2005;366:397–408
  2. Browne K, Jones RN, Weill H, Parkes WR. Asbestos-Related Dis- orders. 3rd ed. Health Environmental Research Online (HERO) US EPA 1994. p.411–505
  3. Powers A, Carbone M. The role of environmental carcinogens, viruses and genetic predisposition in the pathogenesis of me- sothelioma. Cancer Biol Ther 2002;1:348–53
  4. Metintas M, Ozdemir N, Hillerdal G, Uçgun I, Metintas S, Baykul C, et al. Environmental asbestos exposure and malig- nant pleural mesothelioma. Respir Med 1999;93:349–55. 5. de Klerk NH, Musk AW, Williams V, Filion PR, Whitaker D, Shilkin KB. Comparison of measures of exposure to asbestos in for- mer crocidolite workers from Wittenoom Gorge, W. Australia. Am J Ind Med 1996;30:579–87
  5. Metintas M, Hillerdal G, Metintas S. Malignant mesothelioma due to environmental exposure to erionite: Follow-up of a Turkish emigrant cohort. Eur Respir J 1999;13:523–6
  6. Muers MF, Stephens RJ, Fisher P, Darlison L, Higgs CM, Low- ry E, et al. Active symptom control with or without chemo - therapy in the treatment of patients with malignant pleural mesothelioma (MS01): A multicentre randomised trial. Lancet 2008;371:1685–94
  7. Sterman DH, Kaiser LR, Albelda SM. Advances in the treatment of malignant pleural mesothelioma. Chest 1999;116:504–20
  8. Antman K, Shemin R, Ryan L, Klegar K, Osteen R, Herman T, et al. Malignant mesothelioma: Prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965- 1985. J Clin Oncol 1988;6:147–53
  9. Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural meso - thelioma: Results in 183 patients. J Thorac Cardiovasc Surg 1999;117:54–63
  10. Klinger MH, Jelkmann W. Role of blood platelets in infection and inflammation. J Interferon Cytokine Res 2002;22:913–22
  11. Li QQ, Lu ZH, Yang L, Lu M, Zhang XT, Li J, et al. Neutrophil count and the inflammation-based glasgow prognostic score predict survival in patients with advanced gastric cancer receiving first-line chemotherapy. Asian Pac J Cancer Prev 2014;15:945–50
  12. Van Glabbeke M, van Oosterom AT, Oosterhuis JW, Mouridsen H, Crowther D, Somers R, et al. Prognostic factors for the out- come of chemotherapy in advanced soft tissue sar